Arana completes Phase II
Monday, 09 March, 2009
Arana Therapeutics, currently the subject of a takeover bid by US company Cephalon, has completed its Phase II trial of lead candidate ART621 in psoriasis.
The trial met the primary endpoints of tolerability and safety. Secondary findings included evidence of anti-tumour necrosis factor activity, a reduction in severity in some patients and no antibody responses against the drug, suggesting the drug has low immunogenicity, the company said.
ART621 is a human domain-based antibody directed against TNF. It is currently in two Phase II trials for rheumatoid arthritis in combination with methotrexate.
The study was conducted at the Nucleus Network in Melbourne and CMAX in Adelaide.
Ultra-processed foods linked to poor health, premature death
Evidence suggests a dose-response relationship between ultra-processed food consumption and...
Shorter radiotherapy course proves safe for prostate cancer
A significantly shorter course of radiotherapy for localised prostate cancer is just as safe and...
5-in-1 meningococcal vaccine proves effective
A life-saving meningococcal vaccine covering all five common strains of the deadly disease could...
